LONDON, Dec. 5 /CNW/ - Executives from the global pharmaceutical and
biotech industries converged on London last night to celebrate their
achievements at the third annual Scrip Awards.
John Davis, the managing editor of Scrip World Pharmaceutical News,
opened the proceedings by highlighting progress made by the industry in the
past 12 months, such as the introduction of new products for AIDS/HIV, high
blood pressure and breast and renal cancer. The industry has also played its
part in the public health arena, helping to plan for a possible flu pandemic,
developing medicines for rare and orphan diseases, and stepping up efforts to
treat neglected diseases in developing countries.
Hosted by Dr Phil Hammond, a UK-based GP, writer and broadcaster, the
event was also addressed from New York via video link by Digby, Lord Jones of
Birmingham, UK Minister of State for Trade and Investment. Lord Jones
congratulated not just the winners but all the entrants. He saluted the
achievements of the pharmaceutical industry in the UK, noting the country has
produced 23 Nobel Prize winners in science. Representing 1% of the global
population, the UK produces 5% of the world's science, and pharmaceutical
exports from the UK amount to GBP14 billion.
Taking three of this year's 13 Scrip Awards home to the US was
Schering-Plough. It won Management Team of the Year, sponsored by RSA, Pharma
Company of the year (Large), sponsored by Pharmanet, and CEO Fred Hassan won
the accolade of Executive of the Year, sponsored by Harten group.
Schering-Plough's group vice-president EUCAN Region 1, Francesco Granata said:
"I am pleased and proud to be part of this organisation. Fred and his team
deserved this recognition."
Wyeth Pharmaceuticals had a successful evening, claiming two awards: it
won Best Overall Pipeline, supported by the UK Trade & Investment, while its
mTOR inhibitor Torisel (temsirolimus) won Best New Drug, sponsored by the
Whitehead Mann Partnership.
The BTG Lifetime Achievement Award was presented by BTG's CEO Louise
Makin to Professor Herman Waldmann. Professor Waldmann, who pioneered the
application of humanised monoclonal antibodies as therapeutics, is a renowned
immunologist with more than 450 publications to his name. He was made a Fellow
of the Royal Society in 1990 and has been involved in the creation of several
groundbreaking monoclonal antibody medicines and has held senior posts at
Oxford University - where he is currently Professor at the Sir William Dunn
School of Pathology; and the University of Cambridge, where he has held a
variety of positions including research fellow and reader in therapeutic
immunology. He has also been a visiting professor at the University of
Pennsylvania, Duke University and Stanford University.
The other 2007 winners are:
- Best Partnership Alliance sponsored by Movianto: Vertex Pharmaceuticals
and Janssen Pharmaceutica for the worldwide development of the
hepatitis C protease inhibitor telaprevir
- Licensing Deal of the Year sponsored by Adamson & Partners:
Oxford BioMedica and Sanofi-Aventis for the development and
commercialisation of Trovax
- Best Contract Research Organisation supported by TrialTrove: Kendle
- Biotech Company of the Year sponsored by Fasken Martineau Stringer
- Pharma Company of the Year (SMEs) sponsored by Pharmanet:
- Corporate Social Responsibility sponsored by the ABPI: Merck & Co for
its Mectizan Donation Programme
- Best Company in an Emerging Market supported by Scrip: Merlion
Pharmaceuticals of Singapore
About Scrip World Pharmaceutical News
Scrip World Pharmaceutical News is the leading provider of news and
analysis for the global pharmaceutical and biotechnology industries. With its
network of journalists in Europe, the US and Asia, Scrip updates its
subscribers daily via the website or direct email alert, and twice weekly in a
print or PDF newsletter. Pharmaceutical companies the world over rely on Scrip
for timely, comprehensive and accurate information on all issues affecting
their business, from new legislation to the latest drug discovery advance.
For further information:
For further information: For Editorial Information Contact: Alex
Shimmings, Editor, Tel: +44(0)20-7017-6954, Email: email@example.com;